Nanobiotix S.A. (NBTX) fair value analysis
Nasdaq · Updated 2026-10-19
NBTX price how computed
Valuation status
Reports in EURNBTX reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for NBTX until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $27.90
- Sector
- Healthcare
- 12-month range
- $15.08–$55.07
- Market cap
- $1.42B
- From 52-week high
- -49.3%
- Shares outstanding
- 50.9M
- Rank in Healthcare by quality score
- #289 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing and commercializing nanomedicine therapies designed to enhance the effectiveness of cancer treatments. The company operates primarily in France and the United States, with a focus on advancing its pipeline of products targeting solid tumors through radiation therapy enhancement and immunotherapy approaches.
NBTX currently ranks #289 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $1.42B
- Revenue (TTM)
- EUR 16.9M
- Net margin
- -622.7%
- EPS (TTM)
- EUR -1.11
- Debt / equity
- 0.00
- Shares outstanding
- 50.9M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 19 · oversold
- 50-day average
- $34.66
- 200-day average
- $33.43
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 4 beat, 1 missed
- Quarter by quarter
- 2026-03 ▲ beat (+100.0%)
2025-09 ▬ met
2025-06 ▲ beat (+63.8%)
2025-03 ▼ miss (-33.9%)
2024-09 ▬ met
2024-06 ▲ beat (+1.9%)
2024-03 ▲ beat (+1.1%)
2023-09 ▬ met
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 1 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $54
- Target vs last price
- +93.5%
What our data shows for NBTX
- Shares are trading in the lower third of their 12-month price range of $15.08–$55.07.
- The 14-day relative strength index sits at an oversold 19.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NBTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent NBTX news
TickrTrends' derived news-sentiment signal for NBTX is currently leaning negative, computed from recent coverage.
- Can J&J’s Partnership Drive More Upside for Nanobiotix? (insidermonkey.com, 2026-09-28)
What people are saying
Follow the NBTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NBTX stock undervalued?
NBTX reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for NBTX until same-currency inputs are available.
What is NBTX's TickrTrends verdict?
NBTX is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does NBTX compare to other Healthcare stocks?
NBTX ranks #289 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NBTX overbought or oversold?
NBTX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does NBTX usually beat earnings estimates?
Over its last 8 reported quarters NBTX beat the consensus estimate 4 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NBTX?
Of 5 analysts covering NBTX, 4 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $54 (+93.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.